Discounted Cash Flow (DCF) Analysis Levered
Knight Therapeutics Inc. (GUD.TO)
$4.85
-0.03 (-0.61%)
All numbers are in Millions, Currency in USD
Free Cash Flow
Year A/P | 2017 Actual | 2018 Actual | 2019 Actual | 2020 Actual | 2021 Actual | 2022 Projected | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected |
Revenue | 8.63 | 12.50 | 47.46 | 199.52 | 243.48 | 649.41 | 1,732.10 | 4,619.86 | 12,322.12 | 32,865.63 |
---|---|---|---|---|---|---|---|---|---|---|
Revenue (%) | ||||||||||
Operating Cash Flow | 23.46 | -5.74 | 4.60 | -12.21 | 44.62 | 321.67 | 857.95 | 2,288.32 | 6,103.43 | 16,279.10 |
Operating Cash Flow (%) | ||||||||||
Capital Expenditure | -0.13 | -3.87 | -2.95 | -20.67 | -224.18 | -183.24 | -488.73 | -1,303.55 | -3,476.83 | -9,273.43 |
Capital Expenditure (%) | ||||||||||
Free Cash Flow | 23.33 | -9.61 | 1.65 | -32.87 | -179.57 | 138.43 | 369.22 | 984.78 | 2,626.60 | 7,005.68 |
Weighted Average Cost Of Capital
Share price | $ 4.85 |
---|---|
Beta | 0.523 |
Diluted Shares Outstanding | 124.52 |
Cost of Debt | |
Tax Rate | -134.30 |
After-tax Cost of Debt | 8.83% |
Risk-Free Rate | |
Market Risk Premium | |
Cost of Equity | 6.213 |
Total Debt | 40.96 |
Total Equity | 603.93 |
Total Capital | 644.89 |
Debt Weighting | 6.35 |
Equity Weighting | 93.65 |
Wacc |
Build Up Free Cash Flow
Year A/P | 2017 Actual | 2018 Actual | 2019 Actual | 2020 Actual | 2021 Actual | 2022 Projected | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected |
Revenue | 8.63 | 12.50 | 47.46 | 199.52 | 243.48 | 649.41 | 1,732.10 | 4,619.86 | 12,322.12 | 32,865.63 |
---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow | 23.46 | -5.74 | 4.60 | -12.21 | 44.62 | 321.67 | 857.95 | 2,288.32 | 6,103.43 | 16,279.10 |
Capital Expenditure | -0.13 | -3.87 | -2.95 | -20.67 | -224.18 | -183.24 | -488.73 | -1,303.55 | -3,476.83 | -9,273.43 |
Free Cash Flow | 23.33 | -9.61 | 1.65 | -32.87 | -179.57 | 138.43 | 369.22 | 984.78 | 2,626.60 | 7,005.68 |
WACC | ||||||||||
PV LFCF | 130.13 | 326.26 | 818.01 | 2,050.94 | 5,142.21 | |||||
SUM PV LFCF | 8,467.55 |
Terminal Value
Growth in perpetuity method: | |
---|---|
Long-term growth rate | |
WACC (%) | 6.38 |
Free cash flow (t + 1) | 7,145.79 |
Terminal Value | 163,145.87 |
Present Value of Terminal Value | 119,750.18 |
Intrinsic Value
Enterprise Value | 128,217.72 |
---|---|
Net Debt | -45.01 |
Equity Value | 128,262.73 |
Shares Outstanding | 124.52 |
Equity Value Per Share | 1,030.04 |